Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Oruka Therapeutics, Inc. (ORKA) had Consolidated Net Income/Loss of $-41.21M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-41.21M |
|
-- |
|
-- |
|
$50.11M |
|
$-50.11M |
|
$8.90M |
|
$-41.21M |
|
$-41.21M |
|
$-41.21M |
|
$-41.21M |
|
|
Consolidated Net Income/Loss |
$-41.21M |
$-41.21M |
|
$-50.11M |
|
$-51.02M |
|
62.87M |
|
62.87M |
|
$-0.55 |
|
$-0.55 |
|
| Balance Sheet Financials | |
$884.56M |
|
$0.28M |
|
$254.84M |
|
$1.14B |
|
$22.97M |
|
-- |
|
$1.88M |
|
$24.84M |
|
$1.11B |
|
$1.11B |
|
$1.11B |
|
61.07M |
|
| Cash Flow Statement Financials | |
$-56.72M |
|
$-425.38M |
|
$703.64M |
|
$46.94M |
|
$268.47M |
|
$221.53M |
|
$14.25M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
38.51 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-56.80M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-3.71% |
|
-3.70% |
|
-3.62% |
|
-3.70% |
|
$18.25 |
|
$-0.90 |
|
$-0.90 |
|